Olatunji Oluwatade, MD
Infectious Disease · Vicksburg, MSNPI 1477677458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 30.2% of the total. Among infectious disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$356
- Merck$257
- Insmed, Inc.$243
- Mylan Specialty L.p.$187
- Viiv Healthcare Company$184
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,25198%
- Education$682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,004 |
| Amgen(2 entities) | 22 | $356 |
| Merck | 14 | $257 |
| Insmed, Inc. | 14 | $243 |
| Mylan Specialty L.p. | 10 | $187 |
| Viiv Healthcare Company | 11 | $184 |
| Pfizer | 5 | $132 |
| Gilead | 6 | $110 |
| Astellas Pharma US Inc | 4 | $92 |
| Theratechnologies Inc. | 4 | $89 |
| Paratek Pharmaceuticals, Inc. | 4 | $74 |
| Lundbeck LLC | 3 | $60 |
| Novo Nordisk | 4 | $55 |
| Melinta Therapeutics, LLC | 4 | $53 |
| Boehringer Ingelheim | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| GSK | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| CSL Behring | 2 | $38 |
| Cumberland Pharmaceuticals, Inc. | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Shionogi Inc | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $19 |
| Dexcom, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Abbott | 1 | $12 |
| Alkermes, Inc. | 1 | $12 |
How this compares
$3,319 in reported general payments places this provider in the 90th percentile of 36 infectious disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 12 | $337,033 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $198,844 |
| CabenuvaCabotegravir/Rilpivirine | 30 | $195,823 |
| DalvanceDalbavancin Hcl | 32 | $174,607 |
| TrogarzoIbalizumab-Uiyk | 13 | $153,766 |
| Daptomycin | 78 | $135,530 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $71,023 |
| ErtapenemErtapenem Sodium | 128 | $46,430 |
| JulucaDolutegravir/Rilpivirine | 13 | $45,659 |
| TrulicityDulaglutide | 30 | $44,057 |
| OzempicSemaglutide | 37 | $44,031 |
| JardianceEmpagliflozin | 44 | $42,947 |
| MounjaroTirzepatide | 25 | $25,930 |
| IsentressRaltegravir Potassium | 11 | $21,610 |
| TruvadaEmtricitabine/Tenofovir (Tdf) | 11 | $20,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $356 | $337,03312 claims |
| GileadBiktarvy, Genvoya, Truvada | $110 | $290,03475 claims |
| Viiv Healthcare CompanyCabenuva, Juluca | $184 | $241,48243 claims |
| AbbVieDalvance, Linzess | $1,004 | $183,67847 claims |
| Theratechnologies Inc.Trogarzo | $89 | $153,76613 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $15 | $69,98755 claims |
| Novo NordiskOzempic, Rybelsus | $55 | $63,53948 claims |
| Boehringer IngelheimJardiance | $49 | $42,94744 claims |
| MerckIsentress, Janumet | $257 | $33,19523 claims |
| GSKTrelegy Ellipta | $40 | $9,52316 claims |
| PfizerEliquis | $132 | $8,48813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 infectious disease providers in Mississippi.
Other infectious disease in Vicksburg
- Jesse PenicoGulfport$49K
- Jo DealJackson$9K
- Svenja AlbrechtJackson$5K
- Satwinder SinghGreenville$2K
- Thompson LiddellHattiesburg$2K
- Rathel NolanJackson$2K
- Jason MossHattiesburg$2K
- Richard FlowersJackson$1K
- Senate AmusuHattiesburg$1K
- Ujjwal DharJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.